“Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s768. doi:10.25251/bqftmw67.